
Gastric Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Gastric Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Drugs In Development, 2022, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.
Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 29, 225, 260, 11, 31, 226, 51 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 10, 12, 2, 1, 12 and 3 molecules, respectively.
Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Drugs In Development, 2022, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.
Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 29, 225, 260, 11, 31, 226, 51 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 10, 12, 2, 1, 12 and 3 molecules, respectively.
Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
1781 Pages
- Introduction
- Global Markets Direct Report Coverage
- Gastric Cancer - Overview
- Gastric Cancer - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Gastric Cancer - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Gastric Cancer - Companies Involved in Therapeutics Development
- Gastric Cancer - Drug Profiles
- Gastric Cancer - Dormant Projects
- Gastric Cancer - Discontinued Products
- Gastric Cancer - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Gastric Cancer, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Number of Products under Development by Companies, 2022 (Contd..4)
- Table 7: Number of Products under Development by Companies, 2022 (Contd..5)
- Table 8: Number of Products under Development by Companies, 2022 (Contd..6)
- Table 9: Number of Products under Development by Companies, 2022 (Contd..7)
- Table 10: Number of Products under Development by Companies, 2022 (Contd..8)
- Table 11: Number of Products under Development by Companies, 2022 (Contd..9)
- Table 12: Number of Products under Development by Companies, 2022 (Contd..10)
- Table 13: Number of Products under Development by Companies, 2022 (Contd..11)
- Table 14: Number of Products under Development by Companies, 2022 (Contd..12)
- Table 15: Number of Products under Development by Companies, 2022 (Contd..13)
- Table 16: Number of Products under Development by Companies, 2022 (Contd..14)
- Table 17: Number of Products under Development by Companies, 2022 (Contd..15)
- Table 18: Number of Products under Development by Companies, 2022 (Contd..16)
- Table 19: Number of Products under Development by Companies, 2022 (Contd..17)
- Table 20: Number of Products under Development by Companies, 2022 (Contd..18)
- Table 21: Number of Products under Development by Companies, 2022 (Contd..19)
- Table 22: Number of Products under Development by Companies, 2022 (Contd..20)
- Table 23: Number of Products under Development by Companies, 2022 (Contd..21)
- Table 24: Number of Products under Development by Companies, 2022 (Contd..22)
- Table 25: Number of Products under Development by Companies, 2022 (Contd..23)
- Table 26: Number of Products under Development by Companies, 2022 (Contd..24)
- Table 27: Number of Products under Development by Companies, 2022 (Contd..25)
- Table 28: Number of Products under Development by Companies, 2022 (Contd..26)
- Table 29: Number of Products under Development by Universities/Institutes, 2022
- Table 30: Number of Products under Development by Universities/Institutes, 2022 (Contd..1)
- Table 31: Products under Development by Companies, 2022
- Table 32: Products under Development by Companies, 2022 (Contd..1)
- Table 33: Products under Development by Companies, 2022 (Contd..2)
- Table 34: Products under Development by Companies, 2022 (Contd..3)
- Table 35: Products under Development by Companies, 2022 (Contd..4)
- Table 36: Products under Development by Companies, 2022 (Contd..5)
- Table 37: Products under Development by Companies, 2022 (Contd..6)
- Table 38: Products under Development by Companies, 2022 (Contd..7)
- Table 39: Products under Development by Companies, 2022 (Contd..8)
- Table 40: Products under Development by Companies, 2022 (Contd..9)
- Table 41: Products under Development by Companies, 2022 (Contd..10)
- Table 42: Products under Development by Companies, 2022 (Contd..11)
- Table 43: Products under Development by Companies, 2022 (Contd..12)
- Table 44: Products under Development by Companies, 2022 (Contd..13)
- Table 45: Products under Development by Companies, 2022 (Contd..14)
- Table 46: Products under Development by Companies, 2022 (Contd..15)
- Table 47: Products under Development by Companies, 2022 (Contd..16)
- Table 48: Products under Development by Companies, 2022 (Contd..17)
- Table 49: Products under Development by Companies, 2022 (Contd..18)
- Table 50: Products under Development by Companies, 2022 (Contd..19)
- Table 51: Products under Development by Companies, 2022 (Contd..20)
- Table 52: Products under Development by Companies, 2022 (Contd..21)
- Table 53: Products under Development by Companies, 2022 (Contd..22)
- Table 54: Products under Development by Companies, 2022 (Contd..23)
- Table 55: Products under Development by Companies, 2022 (Contd..24)
- Table 56: Products under Development by Companies, 2022 (Contd..25)
- Table 57: Products under Development by Companies, 2022 (Contd..26)
- Table 58: Products under Development by Companies, 2022 (Contd..27)
- Table 59: Products under Development by Companies, 2022 (Contd..28)
- Table 60: Products under Development by Companies, 2022 (Contd..29)
- Table 61: Products under Development by Companies, 2022 (Contd..30)
- Table 62: Products under Development by Companies, 2022 (Contd..31)
- Table 63: Products under Development by Companies, 2022 (Contd..32)
- Table 64: Products under Development by Companies, 2022 (Contd..33)
- Table 65: Products under Development by Companies, 2022 (Contd..34)
- Table 66: Products under Development by Companies, 2022 (Contd..35)
- Table 67: Products under Development by Companies, 2022 (Contd..36)
- Table 68: Products under Development by Companies, 2022 (Contd..37)
- Table 69: Products under Development by Companies, 2022 (Contd..38)
- Table 70: Products under Development by Companies, 2022 (Contd..39)
- Table 71: Products under Development by Companies, 2022 (Contd..40)
- Table 72: Products under Development by Companies, 2022 (Contd..41)
- Table 73: Products under Development by Companies, 2022 (Contd..42)
- Table 74: Products under Development by Companies, 2022 (Contd..43)
- Table 75: Products under Development by Companies, 2022 (Contd..44)
- Table 76: Products under Development by Companies, 2022 (Contd..45)
- Table 77: Products under Development by Companies, 2022 (Contd..46)
- Table 78: Products under Development by Companies, 2022 (Contd..47)
- Table 79: Products under Development by Companies, 2022 (Contd..48)
- Table 80: Products under Development by Companies, 2022 (Contd..49)
- Table 81: Products under Development by Companies, 2022 (Contd..50)
- Table 82: Products under Development by Companies, 2022 (Contd..51)
- Table 83: Products under Development by Companies, 2022 (Contd..52)
- Table 84: Products under Development by Companies, 2022 (Contd..53)
- Table 85: Products under Development by Universities/Institutes, 2022
- Table 86: Products under Development by Universities/Institutes, 2022 (Contd..1)
- Table 87: Products under Development by Universities/Institutes, 2022 (Contd..2)
- Table 88: Number of Products by Stage and Target, 2022
- Table 89: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 90: Number of Products by Stage and Target, 2022 (Contd..2)
- Table 91: Number of Products by Stage and Target, 2022 (Contd..3)
- Table 92: Number of Products by Stage and Target, 2022 (Contd..4)
- Table 93: Number of Products by Stage and Target, 2022 (Contd..5)
- Table 94: Number of Products by Stage and Target, 2022 (Contd..6)
- Table 95: Number of Products by Stage and Target, 2022 (Contd..7)
- Table 96: Number of Products by Stage and Target, 2022 (Contd..8)
- Table 97: Number of Products by Stage and Target, 2022 (Contd..9)
- Table 98: Number of Products by Stage and Target, 2022 (Contd..10)
- Table 99: Number of Products by Stage and Target, 2022 (Contd..11)
- Table 100: Number of Products by Stage and Target, 2022 (Contd..12)
- Table 101: Number of Products by Stage and Mechanism of Action, 2022
- Table 102: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 103: Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
- Table 104: Number of Products by Stage and Mechanism of Action, 2022 (Contd..3)
- Table 105: Number of Products by Stage and Mechanism of Action, 2022 (Contd..4)
- Table 106: Number of Products by Stage and Mechanism of Action, 2022 (Contd..5)
- Table 107: Number of Products by Stage and Mechanism of Action, 2022 (Contd..6)
- Table 108: Number of Products by Stage and Mechanism of Action, 2022 (Contd..7)
- Table 109: Number of Products by Stage and Mechanism of Action, 2022 (Contd..8)
- Table 110: Number of Products by Stage and Mechanism of Action, 2022 (Contd..9)
- Table 111: Number of Products by Stage and Mechanism of Action, 2022 (Contd..10)
- Table 112: Number of Products by Stage and Mechanism of Action, 2022 (Contd..11)
- Table 113: Number of Products by Stage and Mechanism of Action, 2022 (Contd..12)
- Table 114: Number of Products by Stage and Route of Administration, 2022
- Table 115: Number of Products by Stage and Molecule Type, 2022
- Table 116: Gastric Cancer – Pipeline by 3SBio Inc, 2022
- Table 117: Gastric Cancer – Pipeline by A28 Therapeutics Inc, 2022
- Table 118: Gastric Cancer – Pipeline by Abbisko Cayman Limited, 2022
- Table 119: Gastric Cancer – Pipeline by AbbVie Inc, 2022
- Table 120: Gastric Cancer – Pipeline by Abclon Inc, 2022
- Table 121: Gastric Cancer – Pipeline by Abion Inc, 2022
- Table 122: Gastric Cancer – Pipeline by ABL Bio Inc, 2022
- Table 123: Gastric Cancer – Pipeline by Abpro Corp, 2022
- Table 124: Gastric Cancer – Pipeline by AbTis Co Ltd, 2022
- Table 125: Gastric Cancer – Pipeline by Accurus Biosciences Inc, 2022
- Table 126: Gastric Cancer – Pipeline by Adaptimmune Therapeutics Plc, 2022
- Table 127: Gastric Cancer – Pipeline by ADC Therapeutics SA, 2022
- Table 128: Gastric Cancer – Pipeline by Advenchen Laboratories LLC, 2022
- Table 129: Gastric Cancer – Pipeline by Affimed GmbH, 2022
- Table 130: Gastric Cancer – Pipeline by AffyImmune Therapeutics Inc, 2022
- Table 131: Gastric Cancer – Pipeline by Agenus Inc, 2022
- Table 132: Gastric Cancer – Pipeline by AIMM Therapeutics BV, 2022
- Table 133: Gastric Cancer – Pipeline by Akeso Inc, 2022
- Table 134: Gastric Cancer – Pipeline by Alkermes Plc, 2022
- Table 135: Gastric Cancer – Pipeline by Alligator Bioscience AB, 2022
- Table 136: Gastric Cancer – Pipeline by Alphamab Oncology, 2022
- Table 137: Gastric Cancer – Pipeline by Alteogen Inc, 2022
- Table 138: Gastric Cancer – Pipeline by AltruBio Inc, 2022
- Table 139: Gastric Cancer – Pipeline by ALX Oncology Holdings Inc, 2022
- Table 140: Gastric Cancer – Pipeline by Ambrx Biopharma Inc, 2022
- Table 141: Gastric Cancer – Pipeline by amcure GmbH, 2022
- Table 142: Gastric Cancer – Pipeline by Amgen Inc, 2022
- Table 143: Gastric Cancer – Pipeline by Aminex Therapeutics Inc, 2022
- Table 144: Gastric Cancer – Pipeline by Amunix Operating Inc, 2022
- Table 145: Gastric Cancer – Pipeline by Andes Biotechnologies, 2022
- Table 146: Gastric Cancer – Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, 2022
- Table 147: Gastric Cancer – Pipeline by Antengene Corp Ltd, 2022
- Table 148: Gastric Cancer – Pipeline by Antikor Biopharma Ltd, 2022
- Table 149: Gastric Cancer – Pipeline by Apollomics Inc, 2022
- Table 150: Gastric Cancer – Pipeline by Apotex Inc, 2022
- Table 151: Gastric Cancer – Pipeline by Aprea Therapeutics Inc, 2022
- Table 152: Gastric Cancer – Pipeline by Aptacure Therapeutics Ltd, 2022
- Table 153: Gastric Cancer – Pipeline by Arbele Ltd, 2022
- Table 154: Gastric Cancer – Pipeline by Arcus Biosciences Inc, 2022
- Table 155: Gastric Cancer – Pipeline by Argonaut Therapeutics Ltd, 2022
- Table 156: Gastric Cancer – Pipeline by Arromax Pharmatech Co Ltd, 2022
- Table 157: Gastric Cancer – Pipeline by Aryogen Pharmed Co, 2022
- Table 158: Gastric Cancer – Pipeline by Asana BioSciences LLC, 2022
- Table 159: Gastric Cancer – Pipeline by Ascelia Pharma AB, 2022
- Table 160: Gastric Cancer – Pipeline by Ascenta Therapeutics Inc, 2022
- Table 161: Gastric Cancer – Pipeline by Ascentage Pharma Group Inc, 2022
- Table 162: Gastric Cancer – Pipeline by Ascentage Pharma Group International, 2022
- Table 163: Gastric Cancer – Pipeline by Ascentawits Pharmaceuticals Ltd, 2022
- Table 164: Gastric Cancer – Pipeline by AskAt Inc, 2022
- Table 165: Gastric Cancer – Pipeline by AskGene Pharma Inc, 2022
- Table 166: Gastric Cancer – Pipeline by Aslan Pharmaceuticals Ltd, 2022
- Table 167: Gastric Cancer – Pipeline by Astellas Pharma Inc, 2022
- Table 168: Gastric Cancer – Pipeline by AstraZeneca Plc, 2022
- Table 169: Gastric Cancer – Pipeline by Aurigene Discovery Technologies Ltd, 2022
- Table 170: Gastric Cancer – Pipeline by Aurora BioPharma Inc, 2022
- Table 171: Gastric Cancer – Pipeline by Avvinity Therapeutics Ltd, 2022
- Table 172: Gastric Cancer – Pipeline by Basilea Pharmaceutica Ltd, 2022
- Table 173: Gastric Cancer – Pipeline by Bavarian Nordic AS, 2022
- Table 174: Gastric Cancer – Pipeline by Bayer AG, 2022
- Table 175: Gastric Cancer – Pipeline by BeiGene Ltd, 2022
- Table 176: Gastric Cancer – Pipeline by Beijing BGI-GBI Biotech Co Ltd, 2022
- Table 177: Gastric Cancer – Pipeline by Beijing Biostar Technologies Ltd, 2022
- Table 178: Gastric Cancer – Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, 2022
- Table 179: Gastric Cancer – Pipeline by Beijing Immunochina Pharmaceuticals Co Ltd, 2022
- Table 180: Gastric Cancer – Pipeline by Beijing Jingda Biotechnology Co Ltd, 2022
- Table 181: Gastric Cancer – Pipeline by Beijing Konruns Pharmaceutical Co Ltd, 2022
- Table 182: Gastric Cancer – Pipeline by Beijing Mabworks Biotech Co Ltd, 2022
- Table 183: Gastric Cancer – Pipeline by Beijing Scitech-MQ Pharmaceuticals Ltd, 2022
- Table 184: Gastric Cancer – Pipeline by Beijing Syngentech Co Ltd, 2022
- Table 185: Gastric Cancer – Pipeline by Beijing Wuhe Boao Pharmaceutical Technology Development Co Ltd, 2022
- Table 186: Gastric Cancer – Pipeline by Beijng Immunoah Pharma Tech Co Ltd, 2022
- Table 187: Gastric Cancer – Pipeline by Bellicum Pharmaceuticals Inc, 2022
- Table 188: Gastric Cancer – Pipeline by Betta Pharmaceuticals Co Ltd, 2022
- Table 189: Gastric Cancer – Pipeline by Bicara Therapeutics Inc, 2022
- Table 190: Gastric Cancer – Pipeline by Bicycle Therapeutics Plc, 2022
- Table 191: Gastric Cancer – Pipeline by Bika Biotechnology Guanzhou Co Ltd, 2022
- Table 192: Gastric Cancer – Pipeline by Bio-Synectics Inc, 2022
- Table 193: Gastric Cancer – Pipeline by Bio-Thera Solutions Ltd, 2022
- Table 194: Gastric Cancer – Pipeline by BioAtla Inc, 2022
- Table 195: Gastric Cancer – Pipeline by BioEclipse Therapeutics Inc, 2022
- Table 196: Gastric Cancer – Pipeline by BioIntegrator, 2022
- Table 197: Gastric Cancer – Pipeline by BioInvent International AB, 2022
- Table 198: Gastric Cancer – Pipeline by BioLineRx Ltd, 2022
- Table 199: Gastric Cancer – Pipeline by BioMed Valley Discoveries Inc, 2022
- Table 200: Gastric Cancer – Pipeline by Biomunex Pharmaceuticals, 2022
- Table 201: Gastric Cancer – Pipeline by BioNTech SE, 2022
- Table 202: Gastric Cancer – Pipeline by Biosion Inc, 2022
- Table 203: Gastric Cancer – Pipeline by Biosplice Therapeutics Inc, 2022
- Table 204: Gastric Cancer – Pipeline by BioSyngen Pte Ltd, 2022
- Table 205: Gastric Cancer – Pipeline by Biotecnol Ltd, 2022
- Table 206: Gastric Cancer – Pipeline by Biotheus Inc, 2022
- Table 207: Gastric Cancer – Pipeline by Bioviz Technologies Pvt Ltd, 2022
- Table 208: Gastric Cancer – Pipeline by BJ Bioscience Inc, 2022
- Table 209: Gastric Cancer – Pipeline by Bliss Biopharmaceutical (Hangzhou) Co Ltd, 2022
- Table 210: Gastric Cancer – Pipeline by Blueprint Medicines Corp, 2022
- Table 211: Gastric Cancer – Pipeline by Boehringer Ingelheim International GmbH, 2022
- Table 212: Gastric Cancer – Pipeline by Bold Therapeutics Inc, 2022
- Table 213: Gastric Cancer – Pipeline by Bolt Biotherapeutics Inc, 2022
- Table 214: Gastric Cancer – Pipeline by BreakBio Corp, 2022
- Table 215: Gastric Cancer – Pipeline by BrickBio Inc, 2022
- Table 216: Gastric Cancer – Pipeline by BridgeBio Pharma Inc, 2022
- Table 217: Gastric Cancer – Pipeline by BrightGene Bio-Medical Technology Co Ltd, 2022
- Table 218: Gastric Cancer – Pipeline by Bristol-Myers Squibb Co, 2022
- Table 219: Gastric Cancer – Pipeline by Byondis BV, 2022
- Table 220: Gastric Cancer – Pipeline by Calithera Biosciences Inc, 2022
- Table 221: Gastric Cancer – Pipeline by CalyGene Biotechnology Inc, 2022
- Table 222: Gastric Cancer – Pipeline by CanBas Co Ltd, 2022
- Table 223: Gastric Cancer – Pipeline by Carisma Therapeutics Inc, 2022
- Table 224: Gastric Cancer – Pipeline by Carrier (Beijing) Pharmaceutical Co Ltd, 2022
- Table 225: Gastric Cancer – Pipeline by CARsgen Therapeutics Ltd, 2022
- Table 226: Gastric Cancer – Pipeline by CAS-Lamvac Biotech Co Ltd, 2022
- Table 227: Gastric Cancer – Pipeline by Catalent Inc, 2022
- Table 228: Gastric Cancer – Pipeline by Catamaran Bio Inc, 2022
- Table 229: Gastric Cancer – Pipeline by Cedilla Therapeutics, 2022
- Table 230: Gastric Cancer – Pipeline by Celldex Therapeutics Inc, 2022
- Table 231: Gastric Cancer – Pipeline by Cellestia Biotech AG, 2022
- Table 232: Gastric Cancer – Pipeline by Cellid Co Ltd, 2022
- Table 233: Gastric Cancer – Pipeline by Cellivery Therapeutics Inc, 2022
- Table 234: Gastric Cancer – Pipeline by Cellix Bio Pvt Ltd, 2022
- Table 235: Gastric Cancer – Pipeline by Cello Therapeutics Inc, 2022
- Table 236: Gastric Cancer – Pipeline by Celon Pharma SA, 2022
- Table 237: Gastric Cancer – Pipeline by Celularity Inc, 2022
- Table 238: Gastric Cancer – Pipeline by Cend Therapeutics Inc, 2022
- Table 239: Gastric Cancer – Pipeline by Centrymed Pharmaceutical Inc, 2022
- Table 240: Gastric Cancer – Pipeline by CGeneTech (Suzhou China) Co Ltd, 2022
- Table 241: Gastric Cancer – Pipeline by Cheetah Cell Therapeutics Co Ltd, 2022
- Table 242: Gastric Cancer – Pipeline by Chengdu Jinrui Foundation Biotechnology Co Ltd, 2022
- Table 243: Gastric Cancer – Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, 2022
- Table 244: Gastric Cancer – Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
- Table 245: Gastric Cancer – Pipeline by Chimeric Therapeutics Ltd, 2022
- Table 246: Gastric Cancer – Pipeline by China Immunotech (Beijing) Biotechnology Co Ltd, 2022
- Table 247: Gastric Cancer – Pipeline by Chong Kun Dang Pharmaceutical Corporation, 2022
- Table 248: Gastric Cancer – Pipeline by Chongqing Precision Biotech Co Ltd, 2022
- Table 249: Gastric Cancer – Pipeline by Chugai Pharmaceutical Co Ltd, 2022
- Table 250: Gastric Cancer – Pipeline by Cloaked Therapeutics LLC, 2022
- Table 251: Gastric Cancer – Pipeline by CMG Pharmaceutical Co Ltd, 2022
- Table 252: Gastric Cancer – Pipeline by CNBX Pharmaceuticals Inc, 2022
- Table 253: Gastric Cancer – Pipeline by Codiak BioSciences Inc, 2022
- Table 254: Gastric Cancer – Pipeline by Coherent Biopharma, 2022
- Table 255: Gastric Cancer – Pipeline by Conagen Inc, 2022
- Table 256: Gastric Cancer – Pipeline by Convalife, 2022
- Table 257: Gastric Cancer – Pipeline by CSPC Pharmaceutical Group Ltd, 2022
- Table 258: Gastric Cancer – Pipeline by CStone Pharmaceuticals Co Ltd, 2022
- Table 259: Gastric Cancer – Pipeline by CTG Pharma Ltd, 2022
- Table 260: Gastric Cancer – Pipeline by Cue Biopharma Inc, 2022
- Table 261: Gastric Cancer – Pipeline by Cumberland Pharmaceuticals Inc, 2022
- Table 262: Gastric Cancer – Pipeline by Curegenix Inc, 2022
- Table 263: Gastric Cancer – Pipeline by CureLab Oncology Inc, 2022
- Table 264: Gastric Cancer – Pipeline by CureMeta LLC, 2022
- Table 265: Gastric Cancer – Pipeline by Cytodyn Inc, 2022
- Table 266: Gastric Cancer – Pipeline by CytoImmune Therapeutics Inc, 2022
- Table 267: Gastric Cancer – Pipeline by CytomX Therapeutics Inc, 2022
- Table 268: Gastric Cancer – Pipeline by D3 Bio Inc, 2022
- Table 269: Gastric Cancer – Pipeline by Daiichi Sankyo Co Ltd, 2022
- Table 270: Gastric Cancer – Pipeline by Defence Therapeutics Inc, 2022
- Table 271: Gastric Cancer – Pipeline by Delta-Fly Pharma Inc, 2022
- Table 272: Gastric Cancer – Pipeline by Diaccurate, 2022
- Table 273: Gastric Cancer – Pipeline by DiNonA Inc, 2022
- Table 274: Gastric Cancer – Pipeline by DM Bio Ltd, 2022
- Table 275: Gastric Cancer – Pipeline by DNAtrix Inc, 2022
- Table 276: Gastric Cancer – Pipeline by Dongguan Daxin Biotechnology Co Ltd, 2022
- Table 277: Gastric Cancer – Pipeline by Dragonboat Biopharmaceutical (Shanghai) Co Ltd, 2022
- Table 278: Gastric Cancer – Pipeline by Duo Oncology Inc, 2022
- Table 279: Gastric Cancer – Pipeline by Dyadic International Inc, 2022
- Table 280: Gastric Cancer – Pipeline by DynamiCure Biotechnology LLC, 2022
- Table 281: Gastric Cancer – Pipeline by Eddingpharm Inc, 2022
- Table 282: Gastric Cancer – Pipeline by Eden Biologics Inc, 2022
- Table 283: Gastric Cancer – Pipeline by Eisai Co Ltd, 2022
- Table 284: Gastric Cancer – Pipeline by Eli Lilly and Co, 2022
- Table 285: Gastric Cancer – Pipeline by Ella Therapeutics Ltd, 2022
- Table 286: Gastric Cancer – Pipeline by Ellipses Pharma Ltd, 2022
- Table 287: Gastric Cancer – Pipeline by Elpiscience Biopharma Ltd, 2022
- Table 288: Gastric Cancer – Pipeline by Elucida Oncology Inc, 2022
- Table 289: Gastric Cancer – Pipeline by EOS Biosciences Inc, 2022
- Table 290: Gastric Cancer – Pipeline by EpimAb Biotherapeutics Inc, 2022
- Table 291: Gastric Cancer – Pipeline by EpiThany Inc, 2022
- Table 292: Gastric Cancer – Pipeline by Epsilogen Ltd, 2022
- Table 293: Gastric Cancer – Pipeline by ERYTECH Pharma SA, 2022
- Table 294: Gastric Cancer – Pipeline by Etern BioPharma Co Ltd, 2022
- Table 295: Gastric Cancer – Pipeline by eTheRNA Immunotherapies NV, 2022
- Table 296: Gastric Cancer – Pipeline by Eutilex Co Ltd, 2022
- Table 297: Gastric Cancer – Pipeline by Evopoint Bioscience Co Ltd, 2022
- Table 298: Gastric Cancer – Pipeline by Excelmab Inc, 2022
- Table 299: Gastric Cancer – Pipeline by Exeliom Biosciences SAS, 2022
- Table 300: Gastric Cancer – Pipeline by Exelixis Inc, 2022
- Table 301: Gastric Cancer – Pipeline by EXUMA Biotech Inc, 2022
- Table 302: Gastric Cancer – Pipeline by F-star Therapeutics Inc, 2022
- Table 303: Gastric Cancer – Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Table 304: Gastric Cancer – Pipeline by f5 Therapeutics Inc, 2022
- Table 305: Gastric Cancer – Pipeline by Faron Pharmaceuticals Oy, 2022
- Table 306: Gastric Cancer – Pipeline by Fate Therapeutics Inc, 2022
- Table 307: Gastric Cancer – Pipeline by Frost Biologic Inc, 2022
- Table 308: Gastric Cancer – Pipeline by Fusion Pharmaceuticals Inc, 2022
- Table 309: Gastric Cancer – Pipeline by FutureGen Biopharm Technology Co Ltd, 2022
- Table 310: Gastric Cancer – Pipeline by G+FLAS Life Sciences Inc, 2022
- Table 311: Gastric Cancer – Pipeline by GAiA BioMedicine Inc, 2022
- Table 312: Gastric Cancer – Pipeline by Galecto Inc, 2022
- Table 313: Gastric Cancer – Pipeline by GC Biopharma Corp, 2022
- Table 314: Gastric Cancer – Pipeline by Geneius Biotechnology Inc, 2022
- Table 315: Gastric Cancer – Pipeline by Genentech USA Inc, 2022
- Table 316: Gastric Cancer – Pipeline by GeneQuantum Healthcare Suzhou Co Ltd, 2022
- Table 317: Gastric Cancer – Pipeline by GeneScience Pharmaceuticals Co Ltd, 2022
- Table 318: Gastric Cancer – Pipeline by Genexine Inc, 2022
- Table 319: Gastric Cancer – Pipeline by GenoImmune Therapeutics Biotechnology Co Ltd, 2022
- Table 320: Gastric Cancer – Pipeline by Genome & Co, 2022
- Table 321: Gastric Cancer – Pipeline by Genor BioPharma Co Ltd, 2022
- Table 322: Gastric Cancer – Pipeline by GI Innovation Co Ltd, 2022
- Table 323: Gastric Cancer – Pipeline by Gilead Sciences Inc, 2022
- Table 324: Gastric Cancer – Pipeline by GLG Pharma SA, 2022
- Table 325: Gastric Cancer – Pipeline by GlycoNex Inc, 2022
- Table 326: Gastric Cancer – Pipeline by Glycotope GmbH, 2022
- Table 327: Gastric Cancer – Pipeline by GO Therapeutics Inc, 2022
- Table 328: Gastric Cancer – Pipeline by Good T Cells Inc, 2022
- Table 329: Gastric Cancer – Pipeline by Green Cross LabCell Corp, 2022
- Table 330: Gastric Cancer – Pipeline by Grid Therapeutics LLC, 2022
- Table 331: Gastric Cancer – Pipeline by GSK plc, 2022
- Table 332: Gastric Cancer – Pipeline by GT Biopharma Inc, 2022
- Table 333: Gastric Cancer – Pipeline by Guangdong Yinzhu Pharmaceutical Technology Co Ltd, 2022
- Table 334: Gastric Cancer – Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, 2022
- Table 335: Gastric Cancer – Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, 2022
- Table 336: Gastric Cancer – Pipeline by Guangzhou Doublle Bioproduct Inc, 2022
- Table 337: Gastric Cancer – Pipeline by Guangzhou Yinming Biomedical Technology Co Ltd, 2022
- Table 338: Gastric Cancer – Pipeline by Haikou Qili Pharmaceutical Co Ltd, 2022
- Table 339: Gastric Cancer – Pipeline by HaimBio Ltd, 2022
- Table 340: Gastric Cancer – Pipeline by Hangzhou Bensheng Pharmaceutical Co Ltd, 2022
- Table 341: Gastric Cancer – Pipeline by Hangzhou DAC Biotech Co Ltd, 2022
- Table 342: Gastric Cancer – Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
- Table 343: Gastric Cancer – Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2022
- Table 344: Gastric Cancer – Pipeline by Harbour BioMed (Guangzhou) Co Ltd, 2022
- Table 345: Gastric Cancer – Pipeline by HebeCell Corp, 2022
- Table 346: Gastric Cancer – Pipeline by Hebei Senlang Biotechnology Co Ltd, 2022
- Table 347: Gastric Cancer – Pipeline by Helixmith Co Ltd, 2022
- Table 348: Gastric Cancer – Pipeline by Hibercell Inc, 2022
- Table 349: Gastric Cancer – Pipeline by HiFiBiO Therapeutics Inc, 2022
- Table 350: Gastric Cancer – Pipeline by Highlight Therapeutics SL, 2022
- Table 351: Gastric Cancer – Pipeline by Hillstream BioPharma Inc, 2022
- Table 352: Gastric Cancer – Pipeline by HitGen Inc, 2022
- Table 353: Gastric Cancer – Pipeline by Horizon Therapeutics Plc, 2022
- Table 354: Gastric Cancer – Pipeline by Huabo Biopharm (Shanghai) Co Ltd, 2022
- Table 355: Gastric Cancer – Pipeline by Huadao Shanghai Biomedical Co Ltd, 2022
- Table 356: Gastric Cancer – Pipeline by Huahui Anjian (Beijing) Biotechnology Co Ltd, 2022
- Table 357: Gastric Cancer – Pipeline by Hummingbird Bioscience Pte Ltd, 2022
- Table 358: Gastric Cancer – Pipeline by Hutchison MediPharma Ltd, 2022
- Table 359: Gastric Cancer – Pipeline by I-Mab, 2022
- Table 360: Gastric Cancer – Pipeline by Ideaya Biosciences Inc, 2022
- Table 361: Gastric Cancer – Pipeline by Idience Co Ltd, 2022
- Table 362: Gastric Cancer – Pipeline by IGM Biosciences Inc, 2022
- Table 363: Gastric Cancer – Pipeline by ImCheck Therapeutics SAS, 2022
- Table 364: Gastric Cancer – Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, 2022
- Table 365: Gastric Cancer – Pipeline by Immunisbio Co Ltd, 2022
- Table 366: Gastric Cancer – Pipeline by ImmunityBio Inc, 2022
- Table 367: Gastric Cancer – Pipeline by Immunocore Holdings Plc, 2022
- Table 368: Gastric Cancer – Pipeline by Immunocore Limited, 2022
- Table 369: Gastric Cancer – Pipeline by Immunomet Therapeutics Inc, 2022
- Table 370: Gastric Cancer – Pipeline by Immunomic Therapeutics Inc, 2022
- Table 371: Gastric Cancer – Pipeline by Immunotech Biopharm Ltd, 2022
- Table 372: Gastric Cancer – Pipeline by ImmVirX Pty Ltd, 2022
- Table 373: Gastric Cancer – Pipeline by Imugene Ltd, 2022
- Table 374: Gastric Cancer – Pipeline by Incyte Corp, 2022
- Table 375: Gastric Cancer – Pipeline by Inhibrx Inc, 2022
- Table 376: Gastric Cancer – Pipeline by Innate Pharma SA, 2022
- Table 377: Gastric Cancer – Pipeline by Inner Mongolia Qite Biotechnology (Group) Co Ltd, 2022
- Table 378: Gastric Cancer – Pipeline by Innovative Cellular Therapeutics Co Ltd, 2022
- Table 379: Gastric Cancer – Pipeline by Innovent Biologics Inc, 2022
- Table 380: Gastric Cancer – Pipeline by Inovio Pharmaceuticals Inc, 2022
- Table 381: Gastric Cancer – Pipeline by Intocell Inc, 2022
- Table 382: Gastric Cancer – Pipeline by Intra-Immusg Pvt Ltd, 2022
- Table 383: Gastric Cancer – Pipeline by InxMed (Beijing) Co Ltd, 2022
- Table 384: Gastric Cancer – Pipeline by Ipsen SA, 2022
- Table 385: Gastric Cancer – Pipeline by Istari Oncology Inc, 2022
- Table 386: Gastric Cancer – Pipeline by Ithax Pharmaceuticals Inc, 2022
- Table 387: Gastric Cancer – Pipeline by JenKem Technology Co Ltd, 2022
- Table 388: Gastric Cancer – Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, 2022
- Table 389: Gastric Cancer – Pipeline by Jiangsu Atom Bioscience and Pharmaceutical Co Ltd, 2022
- Table 390: Gastric Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Table 391: Gastric Cancer – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, 2022
- Table 392: Gastric Cancer – Pipeline by Jina Pharmaceuticals Inc, 2022
- Table 393: Gastric Cancer – Pipeline by Jiuzhitang Co Ltd, 2022
- Table 394: Gastric Cancer – Pipeline by Johnson & Johnson, 2022
- Table 395: Gastric Cancer – Pipeline by Joint Biosciences Ltd, 2022
- Table 396: Gastric Cancer – Pipeline by Jounce Therapeutics Inc, 2022
- Table 397: Gastric Cancer – Pipeline by JW Pharmaceutical Corp, 2022
- Table 398: Gastric Cancer – Pipeline by Karyo Biologics LLC, 2022
- Table 399: Gastric Cancer – Pipeline by Karyopharm Therapeutics Inc, 2022
- Table 400: Gastric Cancer – Pipeline by KeyMed Biosciences Inc, 2022
- Table 401: Gastric Cancer – Pipeline by Keythera Pharmaceuticals Co Ltd, 2022
- Table 402: Gastric Cancer – Pipeline by Kintor Pharmaceutical Ltd, 2022
- Table 403: Gastric Cancer – Pipeline by Kirilys Therapeutics Inc, 2022
- Table 404: Gastric Cancer – Pipeline by KLUS Pharma Inc, 2022
- Table 405: Gastric Cancer – Pipeline by Komipharm International Co Ltd, 2022
- Table 406: Gastric Cancer – Pipeli
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.